Analyzing the Price-to-Earnings Ratio of Quince Therapeutics Inc (QNCX)
The 36-month beta value for QNCX is also noteworthy at 1.04. There are mixed opinions on the stock, with 1 analysts rating it as a “buy”, 0 rating it as “overweight”, 4 rating it as “hold”, and 0 rating it as “sell”. The public float for QNCX is 48.34M, and at present, short sellers hold … Read more